Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

Table 1 Treatment with Ang1 and Ang2 inhibitors modulates the phenotype of human tumor cells

The human ovarian cancer cell line OV17-1 (A), and human breast cancer cell line MDA-MB-231 (B) were treated with the Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL, respectively) or control (human IgG1-Fc at 26 μg/mL) for 3 days
Cells were then harvested and analyzed by flow cytometry for expression of surface markers reported to be involved in CTL lysis (HLA-A2, CEA, MUC-1, ICAM-1, calreticulin, Fas, Trail-R1 and Trail-R2). Data indicate percentage of positive cells; MFI is in parentheses. Gating was performed using isotype controls Bold values indicate marker upregulation of > 10 % in percentage or MFI compared to controls